EMAIL THIS PAGE TO A FRIEND

Clinical cancer research : an official journal of the American Association for Cancer Research

Autophagy inhibition augments the anticancer effects of epirubicin treatment in anthracycline-sensitive and -resistant triple-negative breast cancer.


PMID 24721646

Abstract

Triple-negative breast cancers (TNBC) are defined by a lack of expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (ERBB2/HER2). Although initially responsive to chemotherapy, most recurrent TNBCs develop resistance, resulting in disease progression. Autophagy is a lysosome-mediated degradation and recycling process that can function as an adaptive survival response during chemotherapy and contribute to chemoresistance. Our goal was to determine whether autophagy inhibition improves treatment efficacy in TNBC cells in tumors either sensitive or refractory to anthracyclines. We used in vitro and in vivo models of TNBC using cell lines sensitive to epirubicin and other anthracyclines, as well as derivative lines, resistant to the same drugs. We assessed basal autophagy levels and the effects of chemotherapy on autophagy in parental and resistant cells. Applying various approaches to inhibit autophagy alone and in combination with chemotherapy, we assessed the effects on cell viability in vitro and tumor growth rates in vivo. We demonstrated that epirubicin induced autophagic flux in TNBC cells. Epirubicin-resistant lines exhibited at least 1.5-fold increased basal autophagy levels and, when treated with autophagy inhibitors, showed a significant loss in viability, indicating dependence of resistant cells on autophagy for survival. Combination of epirubicin with the autophagy inhibitor hydroxychloroquine resulted in a significant reduction in tumor growth compared with monotherapy with epirubicin. Autophagy inhibition enhances therapeutic response in both anthracycline-sensitive and -resistant TNBC and may be an effective new treatment strategy for this disease.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SAB4200361
Anti-LC3B antibody, Mouse monoclonal, clone LC3B-6, purified from hybridoma cell culture
SAB2700738
Anti-Map1lc3b antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB3501065
Anti-MAP1LC3B antibody produced in rabbit, affinity isolated antibody
B5283 Anti-Rabbit IgG (γ-chain specific)−Biotin antibody, Mouse monoclonal, clone RG-96, purified from hybridoma cell culture
A1949 Anti-Rabbit IgG (γ-chain specific)–Peroxidase antibody, Mouse monoclonal, clone RG-96, purified from hybridoma cell culture
R2655
Anti-Rabbit IgG, Native antibody, Mouse monoclonal, clone RabT-50, purified from hybridoma cell culture
1316004
Hydrocortisone, United States Pharmacopeia (USP) Reference Standard
C21H30O5
PHR1014
Hydrocortisone, Pharmaceutical Secondary Standard; Certified Reference Material
C21H30O5
31719
Hydrocortisone, VETRANAL, analytical standard
C21H30O5
H1300000
Hydrocortisone, European Pharmacopoeia (EP) Reference Standard
C21H30O5
Y0001092
Hydrocortisone for peak identification, European Pharmacopoeia (EP) Reference Standard
C21H30O5
WH0081631M1
Monoclonal Anti-MAP1LC3B antibody produced in mouse, clone 4E11, purified immunoglobulin, buffered aqueous solution
SAB1405293
Monoclonal Anti-MAP1LC3B antibody produced in mouse, clone 4G7, purified immunoglobulin, buffered aqueous solution
R1008 Monoclonal Anti-Rabbit IgG (γ-chain specific) antibody produced in mouse, clone RG-96, ascites fluid
A2556 Monoclonal Anti-Rabbit IgG (γ-chain specific)−Alkaline Phosphatase antibody produced in mouse, clone RG-96, purified immunoglobulin, buffered aqueous glycerol solution
R3155 Monoclonal Anti-Rabbit IgG, Native−Peroxidase antibody produced in mouse, clone RabT-50, purified from hybridoma cell culture